HomeCompareZIOP vs EPRT

ZIOP vs EPRT: Dividend Comparison 2026

ZIOP yields 231.03% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ZIOP wins by $281.93M in total portfolio value
10 years
ZIOP
ZIOP
● Live price
231.03%
Share price
$0.87
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$281.99M
Annual income
$152,307,756.02
Full ZIOP calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — ZIOP vs EPRT

📍 ZIOP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodZIOPEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ZIOP + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ZIOP pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZIOP
Annual income on $10K today (after 15% tax)
$19,637.29/yr
After 10yr DRIP, annual income (after tax)
$129,461,592.62/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, ZIOP beats the other by $129,450,397.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZIOP + EPRT for your $10,000?

ZIOP: 50%EPRT: 50%
100% EPRT50/50100% ZIOP
Portfolio after 10yr
$141.03M
Annual income
$76,160,463.44/yr
Blended yield
54.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

ZIOP
No analyst data
Altman Z
-287.0
Piotroski
3/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZIOP buys
0
EPRT buys
0
No recent congressional trades found for ZIOP or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricZIOPEPRT
Forward yield231.03%3.97%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$281.99M$64.3K
Annual income after 10y$152,307,756.02$13,170.85
Total dividends collected$267.75M$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ZIOP vs EPRT ($10,000, DRIP)

YearZIOP PortfolioZIOP Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$33,803$23,102.69$11,212$512.01+$22.6KZIOP
2$109,153$72,984.41$12,689$692.09+$96.5KZIOP
3$337,052$220,258.08$14,521$944.30+$322.5KZIOP
4$996,281$635,635.69$16,841$1,302.88+$979.4KZIOP
5$2,821,960$1,755,939.31$19,841$1,821.64+$2.80MZIOP
6$7,667,803$4,648,304.92$23,818$2,587.47+$7.64MZIOP
7$20,008,593$11,804,044.41$29,230$3,744.65+$19.98MZIOP
8$50,195,948$28,786,753.46$36,816$5,540.38+$50.16MZIOP
9$121,203,020$67,493,355.30$47,806$8,413.17+$121.16MZIOP
10$281,994,987$152,307,756.02$64,324$13,170.85+$281.93MZIOP

ZIOP vs EPRT: Complete Analysis 2026

ZIOPStock

ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

Full ZIOP Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this ZIOP vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZIOP vs SCHDZIOP vs JEPIZIOP vs OZIOP vs KOZIOP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.